Minor New Listings on the Pharmaceutical Benefits Scheme (PBS)

Drugs for the treatment of cardiovascular disease, colon cancer, myeloma and hepatitis C will now be listed on the Pharmaceutical Benefits Scheme thereby cutting the cost to patients.

Page last updated: 09 May 2006

PDF printable version of Minor New Listings on the Pharmaceutical Benefits Scheme (PBS) (PDF 40 KB)

Why is this important?

  • These minor new listings will provide PBS subsidy for a range of drugs. These new drug listings that have a minor cost to the Government include drugs for the treatment of cardiovascular disease, stage III colon cancer, patients with multiple myeloma (a cancer of the blood and immune system) and hepatitis C.

Who will benefit?

  • It is estimated that approximately 27,000 people will commence treatment with these drugs in the first four years of listing. Patients must meet specific criteria to be eligible for PBS subsidised treatment with some of these drugs.

What funding is the Government committing to the initiative?

  • The Government is committing approximately $85.6 million over five years (including funding of $5.9 million in 2005-06).

What has been done in the past?

  • The Government will spend in excess of $6 billion on pharmaceutical benefits in 2005-06.

When will the initiative conclude?

  • This is an ongoing initiative.

In this section